{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:12:32Z","timestamp":1785420752786,"version":"3.56.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant chemoimmunotherapy (NACIT) improves survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), but optimal decisions remain challenging. Clinicopathological factors combined with whole-exome sequencing (WES) and peripheral immune repertoire sequencing (IRS) are promising for identifying prognostic factors to provide insights for clinical decisions and underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with locally advanced HNSCC treated with NACIT across 3 studies were included. Clinicopathological factors labeled with different time points, integrated with WES mutation features, peripheral IRS indices and clonotypes, were analyzed. The endpoints were overall survival (OS), event-free survival (EFS), and major pathological response (MPR). Multivariate logistic regression and Cox proportional hazards models were used to identify independent prognostic factors. Correlation analyses were used to explore the associations between sequencing indices and clinicopathological characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 101 patients were included, with a median follow-up of 38 months, (from 2 to 55 months). Pathology revealed 50 (49.5%) patients with an MPR and 32 (31.7%) with a pathological complete response (pCR). The 3-year OS and EFS rates were 69.4% and 60.1%, respectively. Clinically, performance status (PS) was found to be associated with not only survival but also response. A positive surgical margin caused by extranodal extension significantly affects survival. Biologically, the IRS model based on specific T-cell and B-cell clonotypes demonstrated potential utility in predicting prognosis. High immune repertoire diversity and clonality were significantly correlated with better PS and primary tumor. The WES model showed limited prognostic utility while patients with\n                      <jats:italic>PABPC1<\/jats:italic>\n                      mutation had higher MPR rate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinically, the PS was related to response and survival. ENE associated positive surgical margins remain a threat to survival. Biologically, the IRS model shows preliminary potential for patient stratification, warranting further investigation. Correlations of increased immune diversity with better physical status and primary tumor support earlier NACIT and are worthy of further exploration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1821734","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:32:52Z","timestamp":1785418372000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating clinicopathologic factors with whole-exome sequencing and peripheral immune repertoire sequencing to optimize decision-making in neoadjuvant chemoimmunotherapy for HNSCC"],"prefix":"10.3389","volume":"17","author":[{"given":"Yi-Wei","family":"Zhong","sequence":"first","affiliation":[{"name":"Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University","place":["Guangzhou, China"]},{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"National Center of Stomatology & National Clinical Research Center for Oral Diseases","place":["Beijing, China"]},{"name":"Central Laboratory, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"Peking University Hospital of Stomatology Sanya Division (Sanya Stomatology Center)","place":["Sanya, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu-Gen","family":"An","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"National Center of Stomatology & National Clinical Research Center for Oral Diseases","place":["Beijing, China"]},{"name":"Central Laboratory, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"Peking University Hospital of Stomatology Sanya Division (Sanya Stomatology Center)","place":["Sanya, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"National Center of Stomatology & National Clinical Research Center for Oral Diseases","place":["Beijing, China"]},{"name":"Central Laboratory, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"Peking University Hospital of Stomatology Sanya Division (Sanya Stomatology Center)","place":["Sanya, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"National Center of Stomatology & National Clinical Research Center for Oral Diseases","place":["Beijing, China"]},{"name":"Central Laboratory, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"Peking University Hospital of Stomatology Sanya Division (Sanya Stomatology Center)","place":["Sanya, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Sheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"National Center of Stomatology & National Clinical Research Center for Oral Diseases","place":["Beijing, China"]},{"name":"Central Laboratory, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"Peking University Hospital of Stomatology Sanya Division (Sanya Stomatology Center)","place":["Sanya, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jie","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"National Center of Stomatology & National Clinical Research Center for Oral Diseases","place":["Beijing, China"]},{"name":"Central Laboratory, Peking University School and Hospital of Stomatology","place":["Beijing, China"]},{"name":"Peking University Hospital of Stomatology Sanya Division (Sanya Stomatology Center)","place":["Sanya, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101930","article-title":"Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2025.107218","article-title":"Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis","volume":"162","author":"Wu","year":"2025","journal-title":"Oral Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41467-024-46444-z","article-title":"Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1282629","article-title":"Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0666","article-title":"Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194931","article-title":"Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer","volume":"20","author":"Bianco","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s40425-018-0447-2","article-title":"Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies","volume":"6","author":"Soyano","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6110","article-title":"Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patients","volume":"12","author":"Oku","year":"2023","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2025.107769","article-title":"Response-adapted surgery after neoadjuvant immunochemotherapy in oral squamous cell carcinoma","volume":"171","author":"Fang","year":"2025","journal-title":"Oral Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2025.107809","article-title":"Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: a single-arm phase II clinical trial","volume":"172","author":"Wu","year":"2026","journal-title":"Oral Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001891","article-title":"Neoadjuvant chemoimmunotherapy in resectable locally advanced oral squamous cell carcinoma: a single-center retrospective cohort study","volume":"111","author":"Li","year":"2025","journal-title":"Int J Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1627442","article-title":"Pathological regression patterns following neoadjuvant chemo-immunotherapy in head and neck squamous cell carcinoma: a pilot study","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-0103","article-title":"Characterization of the T-cell receptor repertoire and immune microenvironment in patients with locoregionally advanced squamous cell carcinoma of the head and neck","volume":"23","author":"Saloura","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2501269122","article-title":"Induced B cell receptor diversity predicts PD-1 blockade immunotherapy response","volume":"122","author":"Che","year":"2025","journal-title":"PNAS"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001615","article-title":"Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts","volume":"9","author":"Woolaver","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004512","article-title":"T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100411","article-title":"Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma","volume":"2","author":"Liu","year":"2021","journal-title":"Cell Rep Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2025.107809","article-title":"Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: a single-arm phase II clinical trial","volume":"172","author":"Wu","year":"2025","journal-title":"Oral Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-4693","article-title":"Preoperative chemoimmunotherapy followed by salvage surgery and adjuvant tislelizumab for previously irradiated R HNSCC: a prospective, phase II trial","author":"An","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bth945","article-title":"IMGT\/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J junctions","volume":"20","author":"Yousfi Monod","year":"2004","journal-title":"Bioinformatics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA: A Cancer J For Clin"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106918","article-title":"Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma","volume":"156","author":"Zhao","year":"2024","journal-title":"Oral Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000000489","article-title":"Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial)","volume":"109","author":"Huang","year":"2023","journal-title":"Int J Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2025.107348","article-title":"De-escalated surgery following neoadjuvant chemoimmunotherapy for locally advanced oral squamous cell carcinoma: a retrospective cohort study","volume":"165","author":"Cao","year":"2025","journal-title":"Oral Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2022.2284","article-title":"Outcomes among patients with mucosal head and neck squamous cell carcinoma treated with checkpoint inhibitors","volume":"148","author":"Hobday","year":"2022","journal-title":"JAMA Otolaryngology-- Head Neck Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4117","article-title":"Development and validation of a novel nomogram for individualized prediction of survival in cancer of unknown primary","volume":"27","author":"Raghav","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10616-024-00626-1","article-title":"PABPC1 silencing inhibits pancreatic cancer cell proliferation and EMT, and induces apoptosis via PI3K\/AKT pathway","volume":"76","author":"Zhu","year":"2024","journal-title":"Cytotechnology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/15353702221121631","article-title":"Polyadenylate-binding protein cytoplasmic 1 mediates alternative splicing events of immune-related genes in gastric cancer cells","volume":"247","author":"Xu","year":"2022","journal-title":"Exp Biol Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1186\/s12967-024-05825-0","article-title":"The intratumoral landscape of T cell receptor repertoire in esophageal squamous cell carcinoma","volume":"22","author":"Yang","year":"2024","journal-title":"J Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-19-0398","article-title":"TCR repertoire diversity of peripheral PD-1(+)CD8(+) T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer","volume":"8","author":"Han","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1029","article-title":"Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis","volume":"3","author":"Blumenthal","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1821734\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:32:53Z","timestamp":1785418373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1821734\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1821734"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1821734","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1821734"}}